To address the complicated healthcare landscape in the U.S., Pfizer launched a new direct-to-consumer virtual service called PfizerForAll. It follows Eli Lilly, which launched a similar product in January.
Function Health, a membership-based platform that gives consumers access to more than 100 different lab tests, closed a Series A financing round that brought its total funding to date to $53 million. The round was led by Andreessen Horowitz and included a slew of celebrity investors, including Matt Damon, Zac Efron, Blake Griffin and Colin Kaepernick.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.
Funding for digital health is blowing up, and the sky’s the limit for a healthcare world suddenly, and solidly, committed to tech innovations. Here’s what we can expect to see more of next year.
The company plans to pair its direct-to-consumer genetic testing with Lemonaid’s online coaching and prescription delivery. It plans to buy the company for $400 million in stock and cash.
The startup, where patients access cash-pay telehealth and in-person visits, recently added prescription delivery through Truepill. It’s offering a list of generic medications for $5.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Opportunities exist in many areas of the industry, and patients are hungrier than ever for more engaging and humane experiences. For D2C brands that are ready to capitalize on the changing market, the sky's the limit.
While D2C can enable creativity in customer acquisition and B2B strategies allow for rapid monetization, companies must thoughtfully target consumers, track clinical outcomes, and demonstrate cost-savings.
Covid-19 showed that pharma companies can be nimble and implement changes that prevent processes from weighing down on operations. But which of these operational and strategic changes will stand the test of time and make this year and the future bright for the industry?
The three-year-old digital health startup began trading on the New York Stock Exchange on Thursday. It merged with a subsidiary of Oaktree Capital Management in a deal that valued the company at $1.6 billion.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
A.G. Breitenstein, a founding partner with Optum Ventures, launched FOLX on Thursday. The direct-to-consumer health platform is designed specifically with LGBTQ patients in mind.
The Bay Area hearing device-maker planned to raise $141.3 million in an upsized IPO. Its stock started trading on Nasdaq under the ticker “EAR.”
The direct-to-consumer telehealth startup will go public through a merger with special purpose acquisition company Oaktree Acquisition Corp. The combined entity is expected to be valued at $1.6 billion.
Plume provides access to telehealth consultations for patients seeking gender-affirming hormone therapy. Recently, the startup began partnering with employers to offer its services as a benefit.
Truepill, the startup behind direct-to-consumer health brands like Hims and Nurx, plans to expand into lab testing. The startup raised $75 million in a series C funding round.